Sugi Predict

Sugi Predict / Targets / SCN10A

SCN10A

Sodium channel protein type 10 subunit alpha · Q9Y5Y9 · SCN10A on Sugi Atlas →

60,320 patent compounds predicted against SCN10A, 26,083 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL264502 SCHEMBL264502 0.77 16/20
SCHEMBL265282 SCHEMBL265282 0.62 16/20
SCHEMBL263548 SCHEMBL263548 1.00 15/20
SCHEMBL264547 SCHEMBL264547 0.80 15/20
SCHEMBL263206 SCHEMBL263206 0.77 15/20
SCHEMBL262478 SCHEMBL262478 0.67 15/20
SCHEMBL264685 SCHEMBL264685 0.58 15/20
SCHEMBL261409 SCHEMBL261409 0.50 15/20
SCHEMBL261982 SCHEMBL261982 1.00 14/20
SCHEMBL263595 SCHEMBL263595 1.00 14/20
SCHEMBL263607 SCHEMBL263607 0.76 14/20
SCHEMBL263424 SCHEMBL263424 0.73 14/20
SCHEMBL263240 SCHEMBL263240 0.65 14/20
SCHEMBL261667 SCHEMBL261667 0.64 14/20
SCHEMBL264142 SCHEMBL264142 0.61 14/20
SCHEMBL264402 SCHEMBL264402 0.54 14/20
Pf-04531083 Pf-04531083 (SCHEMBL261689) 1.00 13/20
SCHEMBL261800 SCHEMBL261800 1.00 13/20
SCHEMBL263118 SCHEMBL263118 1.00 13/20
SCHEMBL263433 SCHEMBL263433 0.86 13/20

Clinical trials — most relevant to SCN10A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations PHASE4COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety PHASE3RECRUITING
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome PHASE3RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome PHASE1/PHASE2COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) PHASE1/PHASE2RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome PHASE1/PHASE2RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome PHASE2COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
fMRI-study in Patients With Small Fiber Neuropathy nanUNKNOWN
Single Gene Polymorphism and the Success Rate of Inferior Alveolar Nerve Block nanCOMPLETED
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy nanCOMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom nanRECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Classical Trigeminal Neuralgia and Sodium Channel Mutations nanCOMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation nanRECRUITING
Treatment of Gait Disorders in Children With Dravet Syndrome nanCOMPLETED
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Prospective Study to Determine the Prevalence of Signs of Central Sensitization in Adults With ASD Without Intellectual Developmental Disorders nanRECRUITING
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SCN10A binder may also engage these)

ProteinNameSimilarity
Q62968 — 1.000 Q62968 →
SCN5A Sodium channel protein type 5 subunit alpha 1.000 landscape →
P15389 — 1.000 P15389 →
Q6QIY3 — 1.000 Q6QIY3 →
P15390 — 1.000 P15390 →
O46669 — 0.999 O46669 →
Q28371 — 0.998 Q28371 →
Q9JJV9 — 0.998 Q9JJV9 →
P0DMA5 — 0.996 P0DMA5 →
SCN2A Sodium channel protein type 2 subunit alpha 0.996 landscape →
A2APX8 — 0.995 A2APX8 →
Q9ER60 — 0.995 Q9ER60 →
P04775 — 0.994 P04775 →
SCN4A Sodium channel protein type 4 subunit alpha 0.994 landscape →
SCN3A Sodium channel protein type 3 subunit alpha 0.994 landscape →
Q62205 — 0.994 Q62205 →
O08562 — 0.994 O08562 →
CACNA1G Voltage-dependent T-type calcium channel subunit alpha-1G 0.994 landscape →
O88420 — 0.993 O88420 →
Q9R053 — 0.993 Q9R053 →
SCN8A Sodium channel protein type 8 subunit alpha 0.993 landscape →
P02719 — 0.993 P02719 →
Q28644 — 0.993 Q28644 →
O88457 — 0.992 O88457 →
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 0.992 landscape →
P08104 — 0.992 P08104 →
O97531 — 0.992 O97531 →
B1AWN6 — 0.992 B1AWN6 →
Q2XVR7 — 0.992 Q2XVR7 →
Q6AXP6 — 0.991 Q6AXP6 →